# Oncimmune signs COVID-19 antibody profiling commercial agreement with Cedars-Sinai

- Link: https://www.directorstalkinterviews.com/oncimmune-signs-covid-19-antibody-profiling-commercial-agreement-with-cedars-sinai/412863686
- Published: 2020-10-13T07:55:21+01:00
- Author: Anthony Fox

**Oncimmune Holdings plc** (LON:ONC), the leading global immunodiagnostics group,
has announced that, following its announcement on 6 October that Oncimmune is being
funded by the UK Government to develop a COVID-19 biomarker panel, the Company has
signed a commercial agreement with Cedars-Sinai, California, USA, to provide antibody
profiling in COVID-19 samples as biomarkers for this disease.  Cedars-Sinai is a
world-leading medical research organisation serving more than 1 million people each
year in over 40 locations, with more than 4,500 physicians and nurses and 1,500 
research projects in progress.

Under this agreement, Cedars-Sinai will provide Oncimmune with serum samples from
staff exposed to or infected with the SARS-CoV-2 virus. The project will identify
biomarkers of the COVID-19 disease and compare these to a control set of healthy
patient samples to be provided by Oncimmune. The project will seek to initially 
profile the antibodies of staff working at Cedars-Sinai hospitals to better understand
the effects of the disease in healthcare workers.

On 6 October 2020, we announced Oncimmune’s participation in the IMmunity Profiling
of pAtients with COVID-19 for Therapy and Triage programme to develop and validate
an Infectious Disease NavigAID™ panel designed to predict COVID-19 disease severity
and therapeutic response.  This collaboration with Cedars-Sinai is the first commercial
project to result from this IMPACTT programme.

Cedars-Sinai will also contribute novel antigens to the COVID-19 panel, and in return,
will be the first academic partner to benefit from this IMPACTT programme. Oncimmune
intends to continue to contract commercially with biopharmaceutical companies and
academic organisations for the use of the COVID-19 panel to gain a deeper understanding
of the immune response to the SARS-CoV-2 virus.

> **Adam M Hill, CEO of Oncimmune said:**  “We are delighted to be partnering with
> such a prestigious organisation as Cedars-Sinai on this important programme. Oncimmune
> is responding to the global call for innovations to support the fight against 
> COVID-19 by leveraging our capabilities in immune profiling. In so doing we will
> build on our knowledge of the disease and support the development of vaccines 
> and therapeutics. We expect to announce further development collaborations and
> contracts over the coming months to be followed by contracts with biopharmaceutical
> companies once the COVID-19 panel is fully validated.”

Share on:
